Bio-Path (NASDAQ:BPTH) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Monday, Stock Target Advisor reports. The firm currently has a $28.00 price objective on the stock.

Separately, ValuEngine downgraded Bio-Path from a hold rating to a sell rating in a report on Friday, October 25th.

Bio-Path stock traded down $0.09 during trading on Monday, hitting $9.88. 497 shares of the company were exchanged, compared to its average volume of 65,245. The business’s 50 day moving average is $10.66 and its 200 day moving average is $12.65. Bio-Path has a 52 week low of $1.61 and a 52 week high of $73.52. The company has a market capitalization of $30.75 million, a P/E ratio of -0.69 and a beta of 3.14. The company has a current ratio of 13.85, a quick ratio of 13.85 and a debt-to-equity ratio of 0.02.

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Bio-Path by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock valued at $374,000 after purchasing an additional 2,601 shares during the period. BlackRock Inc. grew its stake in Bio-Path by 17.5% in the 2nd quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock valued at $628,000 after purchasing an additional 6,978 shares during the period. Finally, Morgan Stanley grew its stake in Bio-Path by 19,858.0% in the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after purchasing an additional 19,858 shares during the period. Hedge funds and other institutional investors own 9.43% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Article: What is the outlook for the FAANG stocks?

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.